Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHM-1035
- Development stage
- Preclinical
- Lead developer
- Chemia
- Modality
- Small Molecules
01
Overview
CHM-1035 is an investigational small molecule drug candidate being developed by Chemia, a biotechnology company specializing in AI-driven drug discovery inspired by natural products. The compound is part of Chemia's internal pipeline, which leverages machine learning to explore the chemical space of natural product scaffolds for therapeutic applications. While CHM-1035 is actively being advanced through the discovery and optimization stages, specific details regarding its biological target, mechanism of action, and primary therapeutic indication remain proprietary and have not yet been publicly disclosed by the company.
Beyond the preview
Go deeper on CHM-1035.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHM-1035.